Please assess the completion status of the following clinical trial:

Trial Title: STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 3-5 CKD not on dialysis~* Patients ≥ 70 years of age~* Haemoglobin \< 110g/L at screening~* Transferrin saturation ≥ 15% at screening~Exclusion Criteria:~* Clinical history of type 2 diabetes mellitus~* Anticipating or scheduled to go on renal replacement therapy in the next year, including renal transplant~* Uncontrolled hypertension on two separate measurements during screening~* Use of any erythropoietic protein within 12 weeks of screening

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
- Placebo (Type: PLACEBO_COMPARATOR): Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).